

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. **(Currently Amended)** A pharmaceutical preparation consisting of comprising active compound, gelatin as a binder and fillers and which is free of organic solvent residues, wherein the active compound is levo-thyroxine sodium, and which preparation is in tablet form.

Claim 2. **(Canceled)**

Claim 3. **(Previously Presented)** The pharmaceutical preparation according to claim 1, containing 5 to 400 µg of levothyroxine.

Claim 4. **(Previously Presented)** The pharmaceutical preparation according to claim 1, containing levothyroxine sodium micronized with a particle size of between 5 µm and 25 µm.

Claim 5. **(Previously Presented)** The pharmaceutical preparation according to Claim 1, wherein the filler is lactose, maize starch or microcrystalline cellulose.

Claim 6. **(Previously Presented)** The pharmaceutical preparation according to Claim 1, which is a solid preparation in the form of tablets.

Claim 7. **(Canceled)**

Claim 8. **(Canceled)**

Claim 9. **(Currently Amended)** A pharmaceutical preparation consisting essentially of comprising levo-thyroxine sodium, gelatin as a binder and fillers which is free of organic solvent residues and which is in solid form.

Claim 10. **(Currently Amended)** A pharmaceutical preparation comprising active compound, gelatin as a binder and fillers and which is free of organic solvent residues, wherein the active compound consists essentially of levo-thyroxine sodium and liothyronine sodium, and which preparation is in solid form.

Claim 11. **(Previously Presented)** The pharmaceutical preparation according to claim 9, containing 5 to 400 µg of levothyroxine.

Claim 12. **(Previously Presented)** The pharmaceutical preparation according to claim 9, containing levothyroxine sodium micronized with a particle size of between 5 µm and 25 µm.

Claim 13. **(Previously Presented)** The pharmaceutical preparation according to claim 9, wherein the filler is lactose, maize starch or microcrystalline cellulose.

Claim 14. **(Previously Presented)** The pharmaceutical preparation according to claim 10, containing 5 to 400 µg of levothyroxine.

Claim 15. **(Previously Presented)** The pharmaceutical preparation according to claim 10, containing levothyroxine sodium micronized with a particle size of between 5 µm and 25 µm.

Claim 16 **(Previously Presented)** The pharmaceutical preparation according to claim 10, wherein the filler is lactose, maize starch or microcrystalline cellulose.